Form 8-K REGENXBIO Inc. For: Sep 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Regenxbio settles patent dispute with Sarepta for $39M
September 23, 2026 4:09 PM EDTRegenxbio Inc. (NASDAQ: RGNX) and The Trustees of the University of Pennsylvania reached a settlement agreement with Sarepta Therapeutics Inc. (together with Sarepta Therapeutics Three, LLC) and Catalent Inc. to resolve patent infringement litigation related to Sarepta's Duchenne muscular dystrophy gene therapy ELEVIDYS.
Under the... More
